Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
| ▸ | TTPA | P49638 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9253181 | 0.81 | MEN1 (0.49) | MEN1KMT2ACYP3A4ALOX15LMNA | |
| SCHEMBL7160314 | 0.81 | MEN1 (0.49) | MEN1KMT2ACYP3A4ALOX15LMNA | |
| SCHEMBL19264574 | 0.78 | — | — | |
| SCHEMBL13709416 | 0.76 | ALDH1A1 (0.30) | — | |
| SCHEMBL26189401 | 0.73 | MEN1 (0.38) | MEN1KMT2ACYP3A4ALOX15LMNA | |
| SCHEMBL26189383 | 0.73 | MEN1 (0.38) | MEN1KMT2ACYP3A4ALOX15LMNA | |
| SCHEMBL26412813 | 0.71 | PTPN1 (0.40) | MEN1KMT2ACYP3A4ALOX15LMNA | |
| SCHEMBL26412787 | 0.71 | MEN1 (0.43) | MEN1KMT2ACYP3A4ALOX15LMNA | |
| SCHEMBL13707292 | 0.71 | CA2 (0.30) | — | |
| SCHEMBL16155262 | 0.68 | SMN1; SMN2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451144-B1 | COMPOSITIONS FOR TREATING ACNE COMPRISING PHYTANDIOL AMINE | COREANA COSMETICS CO LTD (KR) | 2010-09-01 | — | — | EP | disclosed |
| US-7582306-B2 | Pseudoceramides and cosmetic compositions comprising the same | COREANA COSMETICS CO., LTD. (KR) | 2009-09-01 | — | — | US | disclosed |
| EP-1480947-B1 | NOVEL PSEUDOCERAMIDES AND COSMETIC COMPOSITIONS COMPRISING THE SAME | COREANA COSMETICS CO LTD (KR) | 2007-08-29 | — | — | EP | disclosed |
| US-7129275-B2 | Compositions for treating acne comprising phytandiol amine | COREANA COSMETICS CO., LTD. (KR) | 2006-10-31 | — | — | US | disclosed |
| US-20050118131-A1 | Novel pseudoceramides and cosmetic compositions comprising the same | COREANA COSMETICS CO., LTD. (KR) | 2005-06-02 | — | — | US | disclosed |
| US-20040258720-A1 | Cosmetics; skin disorders, antiinflammatory agents | COREANA COSMETICS CO., LTD. (KR) | 2004-12-23 | — | — | US | disclosed |
| EP-1480947-A1 | NOVEL PSEUDOCERAMIDES AND COSMETIC COMPOSITIONS COMPRISING THE SAME | Coreana Cosmetics Co., Ltd. (KR) | 2004-12-01 | — | — | EP | disclosed |
| EP-1451144-A1 | COMPOSITIONS FOR TREATING ACNE COMPRISING PHYTANDIOL AMINE | Coreana Cosmetics Co., Ltd. (KR) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003072540-A1 | NOVEL PSEUDOCERAMIDES AND COSMETIC COMPOSITIONS COMPRISING THE SAME | COREANA COSMETICS CO., LTD. (KR) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003037845-A1 | COMPOSITIONS FOR TREATING ACNE COMPRISING PHYTANDIOL AMINE | COREANA COSMETICS CO., LTD. (KR) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258720-A1 | Cosmetics; skin disorders, antiinflammatory agents | CUTA, ACOX3, CYP17A1 | MEN1 539/4885KMT2A 1700/4885CYP3A4 3913/4885 |
| US-20050118131-A1 | Novel pseudoceramides and cosmetic compositions comprising the same | ASAH2, ASAH1, CERS2 | MEN1 1278/4885KMT2A 1076/4885CYP3A4 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.